Enhanced Implantable Intraluminal Device for Efficient Fluid Flow Management

An implantable intraluminal device system with improved fluid flow management and reduced tissue ingrowth, enabling efficient treatment of bodily conduits and side branches.

The original implantable intraluminal device patent has limitations in fluid flow management and tissue ingrowth, which can lead to reduced effectiveness and complications. The new inventive concept addresses these limitations by introducing enhanced fluid flow channels, axial reinforcement members, and a fluid flow control mechanism, enabling more efficient treatment of bodily conduits and side branches.

The enhanced implantable intraluminal device system comprises a primary device with a longitudinal axis and at least one fluid flow channel, and a secondary device with a longitudinal axis and at least one fluid flow channel. The primary device is configured to be deployed through a side branch of a bodily conduit, and the secondary device is configured to be deployed through the primary device. The system includes multiple tubular segments with individual annular stent members and tubular membranes, connected by one or more axial reinforcement members. The stent graft device is configured to operably allow the flow of fluids between the primary conduit and the side branch through flow channels disposed at the peripheral wall of the stent graft device. A fluid flow control mechanism is further included to regulate fluid flow between the primary conduit and the side branch.

The new inventive concept introduces a novel fluid flow management system, which combines axial reinforcement members and a fluid flow control mechanism to efficiently manage fluid flow between bodily conduits and side branches. This is a non-obvious improvement over the original patent, as it requires a deep understanding of fluid dynamics and stent graft device design.

Alternative embodiments of the inventive concept could include varying the number and configuration of tubular segments, using different materials for the stent members and membranes, or incorporating sensors and monitoring systems to optimize fluid flow management. Additionally, the inventive concept could be adapted for use in other bodily conduits, such as cardiovascular or neurological systems.

The enhanced implantable intraluminal device system has significant commercial potential in the medical device industry, particularly in the treatment of cardiovascular and peripheral artery diseases. The target market includes hospitals, medical research institutions, and patients requiring stent graft devices for bodily conduit treatment.